Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)
Editas Medicine (EDIT) posted quarterly Long-Term Investments of $39.2 million for Q2 2024, down 18.5% year-over-year from $48.1 million in Q3 2023, and down 51.37% quarter-over-quarter from $80.6 million in Q1 2024.
Editas Medicine (EDIT) Long-Term Investments (2020 - 2024) Analysis & Trends
Editas Medicine (EDIT) has reported Long-Term Investments for 5 consecutive years, with $39.2 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Long-Term Investments fell 18.5% year-over-year to $39.2 million; the TTM figure through Jun 2024 stood at $39.2 million (down 18.5% YoY), while the FY2023 annual figure was $104.0 million, up 11.74% from the prior year.
- Long-Term Investments slipped to $39.2 million in Q2 2024 per EDIT's latest filing, from $80.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $120.1 million in Q4 2021 and bottomed at $39.2 million in Q2 2024.
- Historically, Long-Term Investments has averaged $82.3 million across 5 years, with a median of $85.5 million in 2021.
- Annual changes were most pronounced in 2021 — Long-Term Investments jumped 115.65% — and 2022, when it tumbled 40.68%.
- Editas Medicine's Long-Term Investments stood at $109.7 million in 2020, then advanced by 9.49% to $120.1 million in 2021, then declined by 22.47% to $93.1 million in 2022, then gained by 11.74% to $104.0 million in 2023, then sank by 62.32% to $39.2 million in 2024.
- Business Quant data shows EDIT's Long-Term Investments at $39.2 million in Q2 2024, $80.6 million in Q1 2024, and $104.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 39.20 Mn |
| Mar 31, 2024 | 80.61 Mn |
| Dec 31, 2023 | 104.02 Mn |
| Sep 30, 2023 | 96.80 Mn |
| Jun 30, 2023 | 48.10 Mn |
| Mar 31, 2023 | 83.34 Mn |
| Dec 31, 2022 | 93.10 Mn |
| Sep 30, 2022 | 58.84 Mn |
| Jun 30, 2022 | 75.10 Mn |
| Mar 31, 2022 | 78.05 Mn |
| Dec 31, 2021 | 120.07 Mn |
| Sep 30, 2021 | 99.20 Mn |
| Jun 30, 2021 | 87.60 Mn |
| Mar 31, 2021 | 97.90 Mn |
| Dec 31, 2020 | 109.66 Mn |
| Sep 30, 2020 | 46.00 Mn |